No Data
No Data
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
Treatment of multiple types of cancer! Roche (RHHBY.US) PD-L1 monoclonal antibody subcutaneous preparation requires only 7 minutes.
Roche (RHHBY.US) announced that its targeted PD-L1 antibody Tecentriq Hybreza (atezolizumab and hyaluronidase) subcutaneous formulation has been approved by the FDA in the USA.
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Merck Keytruda Cuts Mortality Risk in Gastric Cancer by 20%
GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial
Roche Gets FDA Approval for Multiple-Sclerosis Treatment
No Data
No Data